ACOT13

Across TCGA pan-cancer cohorts, ACOT13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACOT13 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACOT13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACOT13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where ACOT13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.450	0.775	.014	8	view →
PDAC	OS	Median	III,IV	0.783	0.386	.023	6	view →
LSCC	OS	Median	II,III,IV	1.000	0.886	.025	4	view →
HNSC	OS	Tertile	IV	0.590	0.857	.013	3	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACOT13–CCRCC (DFS)

Open the CCRCC breakdown →